| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Definium Therapeutics, Inc.$44.1
-1.33 (-2.91%)
C 51Pipeline Score Fair Value Pharma · Clinical
Market Cap
2.45 B
EPS
-2.50
P/E Ratio
-
Value Trade
52.58 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
41.48 M
Operating CF
-42.63 M
Total Assets
401.29 M
Total Liabilities
122.44 M
Equity
278.85 M
D/E Ratio
12,345
6.89 %
Week
-6.56 %
1 Month
30.28 %
3 Month
106.99 %
6 Month
-58.9 %
5 Year
-16.48 %
All Time
Cash Data
Cash Position
373.42 M
Monthly Burn
14.21 M
Runway
24.1 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
3.46 M
52 Week Range
6.35 - 26.25
% held by Insiders
4.97 %
% held by Institutions
57.37 %
Enterprise Value
2.12 B
Total Shares
109.08 M
Short %
11.51 %
Float Shares
107.33 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Definium Therapeutics, Inc.
257Total events
2Upcoming
61Tier-1 (high impact)
2021 – 2028Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutDT120Clinical Data
Subscribe to view catalyst details
TBD
◆Topline ReadoutMM-120Clinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C51
Pipeline Score $2.0B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.8x
rNPV / MCap Top 77%
Small Cap (rank 211 of 912)
Percentile RankDefinium Therapeutics, Inc. carries a moderate pipeline score (51/100), with $3.0B risk-adjusted pipeline value, led by MM120 in ADHD (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MM120 Small molecule | ADHD | Phase 2 | NCT05200936 | 33% | $1.7B | COMPLETED | 53 | - | - | Dec 4, 2023 | - | Feb 27, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MM120 Breakthrough | generalized anxiety disorder (GAD) | Phase 2b | 2025-11-06 | 65% clinical response rate; 48% clinical remission rate at Week 12 Read More | MindMed Reports Q3 2025 Financial Results and Business Updates -- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama ( Read More | |
MM120 Breakthrough | generalized anxiety disorder (GAD) | Phase 2b | 2025-11-06 | 65% clinical response rate; 48% clinical remission rate at Week 12 Read More | MindMed Reports Q3 2025 Financial Results and Business Updates -- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama ( Read More | |
MM120 Breakthrough | generalized anxiety disorder (GAD) | Phase 2b | 2025-11-06 | 65% clinical response rate; 48% clinical remission rate at Week 12 Read More | MindMed Reports Q3 2025 Financial Results and Business Updates -- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama ( Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DFTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DFTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DFTX▼ -2.9%today
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
Definium Therapeutics has launched 'Wired for Worry', an initiative aimed at educating healthcare providers about generalized anxiety disorder (GAD). This program seeks to enhance understanding of GAD's impact and neurobiology, addressing a significant gap in psychiatric care. The initiative reflects Definium's commitment to improving treatment approaches for psychiatric disorders.
Read more →DFTX▲ +5.3%on this news
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
Definium Therapeutics has published a healthcare claims study revealing significant treatment patterns among patients with Generalized Anxiety Disorder (GAD). The study highlights high rates of treatment switching and discontinuation, which may indicate challenges in managing the condition. This research aims to inform better therapeutic strategies for GAD patients.
Read more →DFTXDefinium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Definium Therapeutics, Inc. has successfully closed an upsized public offering totaling $805 million. This offering included the full exercise of the underwriters' option to purchase additional shares, reflecting strong investor interest and confidence in the company's future prospects. The funds raised will likely support Definium's ongoing projects and initiatives.
Read more →DFTX▲ +16.4%on this news· ran to +29% by day 3shared move
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics, Inc. has announced the pricing of its upsized public offering, raising $700 million. This move indicates the company's efforts to strengthen its financial position. Further details regarding the offering's use of proceeds and investor interest were not disclosed in the announcement.
Read more →DFTXDefinium Therapeutics, Inc. Announces Proposed Public Offering
Definium Therapeutics, Inc. has announced a proposed public offering. Details regarding the offering, including the number of shares and pricing, have not been disclosed in the article. The announcement is a standard procedure for companies seeking to raise capital through public markets.
Read more →DFTX▲ +49.8%on this news· ran to +83% by day 3shared move
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
Definium Therapeutics has announced positive topline results from its Phase 3 Emerge study, which evaluated the DT120 orally disintegrating tablet for treating major depressive disorder. The results indicate that DT120 ODT may be an effective new treatment option. This development marks a significant advancement in the company's clinical pipeline.
Read more →DFTX▲ +49.8%on this news· ran to +83% by day 3shared move
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
Definium Therapeutics is set to discuss the topline results from its Phase 3 Emerge Study focused on Major Depressive Disorder. The discussion is scheduled for June 22, 2026. This event marks a significant milestone in the company's research efforts in this area.
Read more →DFTXDefinium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics has announced new employee inducement grants. These grants are part of the company's strategy to attract and retain talent. Further details about the specific grants or their impact on the company were not disclosed in the announcement.
Read more →DFTX▲ +8.5%on this news
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Definium Therapeutics is set to participate in the 2026 Jefferies Global Healthcare Conference. This event will provide a platform for the company to discuss its developments and future plans in the biopharma sector. Further details about the conference and the company's agenda are yet to be disclosed.
Read more →DFTXCorporate Presentation May 2026 This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “ou
Definium Therapeutics, Inc. has released a corporate presentation outlining its progress and future expectations for its lead clinical program, DT120 ODT, which is undergoing five Phase 3 studies. The company anticipates significant readouts in 2026 that could provide substantial commercial opportunities in treating generalized anxiety disorder (GAD) and major depressive disorder (MDD). However, they also recognize the inherent risks associated with drug development, especially concerning regulatory approvals and financial challenges.
Read more →DFTXDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Definium Therapeutics has announced the dosing of the first patient in the Ascend study, which is the second Phase 3 pivotal study for DT120 ODT aimed at treating Major Depressive Disorder. This milestone indicates progress in their clinical development efforts. Further details about the study's design and objectives were not provided.
Read more →DFTXDefinium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Definium Therapeutics has released its financial results for the first quarter of 2026. The report includes recent highlights from the company, although specific details regarding financial performance or developments were not disclosed in the article. The overall tone remains neutral without significant positive or negative news.
Read more →DFTX▲ +6.8%on this news
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Definium Therapeutics will report its first quarter 2026 financial results on May 7, 2026, during a live webcast. The company focuses on developing innovative therapeutics for psychiatric and neurological disorders. The webcast will include a discussion of recent business highlights and a Q&A session for analysts.
Read more →DFTXDefinium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
Definium Therapeutics recently held an Investor and Analyst Day where they discussed advancements related to their DT120 ODT (Lysergide Tartrate) and outlined their commercial strategy. The event served as a platform to engage with stakeholders about the future direction of the company and its product pipeline.
Read more →DFTXDefinium Therapeutics to Participate at Upcoming Investor Conferences and Events
Definium Therapeutics, a late-stage clinical biopharmaceutical company, announced its participation in several upcoming investor conferences. These events include the Needham Virtual Healthcare Conference, the Definium Investor & Analyst Day, and the RBC Capital Markets Global Healthcare Conference. The company aims to showcase its advancements in developing therapeutics for psychiatric and neurological disorders.
Read more →DFTXDefinium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
Definium Therapeutics has announced plans to host an Investor and Analyst Day in New York on April 22, 2026. This event aims to engage with investors and analysts, providing insights into the company's future direction and developments. Further details regarding the agenda and speakers are expected to be released closer to the date.
Read more →DFTXDefinium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no c
Definium Therapeutics announced its full-year 2025 financial results and provided important updates on its clinical trials. The Phase 3 trial for major depressive disorder (MDD), named Emerge, is fully enrolled, with topline data expected by late 2Q 2026. The company also reported approximately 80% enrollment in the Phase 3 generalized anxiety disorder (GAD) study, Voyage, with data expected in early 3Q 2026. Additionally, Definium's financial health appears robust, with sufficient funds to support operations into 2028.
Read more →DFTXDefinium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics, formerly Mind Medicine, Inc., announced its participation in upcoming investor conferences. The management team will present at these events, with audio webcasts available for 90 days post-event. The company aims to revolutionize psychiatric treatment through new therapeutics targeting the underlying causes of mental health disorders.
Read more →DFTXMindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Ta
MindMed has rebranded as Definium Therapeutics, reflecting its commitment to advanced psychiatric treatments. The company is preparing for three Phase 3 readouts for its lead candidate, DT120 ODT, expected in 2026, targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). Definium aims to create scalable therapeutics that directly address the underlying causes of mental health disorders. The rebranding is intended to better represent the company's mission and future ambitions in transforming psychiatry.
Read more →DFTXMindMed Reports Q3 2025 Financial Results and Business Updates -- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (
MindMed reported its Q3 2025 financial results, highlighting ongoing Phase 3 studies for the MM120 Orally Disintegrating Tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company has accelerated its timeline for topline data readout of the Emerge study in MDD to mid-2026, ahead of previous estimates. Additionally, MindMed is initiating a Phase 2a study of MM402 for Autism Spectrum Disorder (ASD) and reported a strong cash position of $209.1 million as of September 30, 2025, supplemented by a recent offering that raised $258.9 million.
Read more →DFTXMind Medicine (MindMed) Inc. Announces Proposed Public Offering
Mind Medicine (MindMed) Inc. announced its intention to offer common shares and pre-funded warrants in an underwritten public offering, subject to market conditions. The company aims to utilize the proceeds for research and development of its product candidates, as well as for working capital. There is no guarantee that the offering will be completed or that it will meet its intended terms. This announcement comes as MindMed focuses on developing treatments for brain health disorders, emphasizing its commitment to innovation in the biopharmaceutical space.
Read more →DFTXCorporate Presentation October 2025 2 This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed", the "Company", "we", "ou r" or "us") solely for informational purposes. This Pres
Mind Medicine (MindMed) Inc. has released a corporate presentation outlining its strategic focus on advancing its lead product, MM120 ODT, through Phase 3 studies for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). The company anticipates significant milestones in 2026, with the potential for substantial commercial opportunities pending successful results. However, it highlights various risks including regulatory approval uncertainties and challenges related to clinical trials. The presentation serves as a foundation for understanding the company’s future path and innovation in neuroscience.
Read more →DFTXJournal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized
The Journal of the American Medical Association has published the results of the first randomized, placebo-controlled clinical trial for MM120 (lysergide D-tartrate) in the treatment of generalized anxiety disorder (GAD). The Phase 2b study showed a significant dose-response relationship, with the 100 µg dose achieving a 65% clinical response rate and 48% remission after 12 weeks. Adverse events were mild and transient, and MM120 has received Breakthrough Therapy Designation from the FDA for GAD, signaling potential advancements in psychiatric treatment options. Further Phase 3 trials are being conducted to confirm these findings.
Read more →DFTXMindMed Reports Q2 2025 Financial Results and Business Updates --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depress
MindMed has reported strong results for Q2 2025, highlighting continued robust enrollment in its three Phase 3 trials for the MM120 Orally Disintegrating Tablet. The company anticipates topline data from these trials in 2026, reflecting ongoing interest from trial participants and sites. Additionally, MindMed has strengthened its leadership team with the appointment of a new Chief Financial Officer, while managing a significant increase in research and development expenses. Despite a notable net loss compared to the previous year, the company's financial strategy supports its ongoing advancements in clinical trials.
Read more →DFTXMindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
MindMed announced the appointment of Brandi L. Roberts, CPA, as its Chief Financial Officer, effective June 2, 2025. Ms. Roberts will oversee the financial strategy and capital planning for MindMed as it advances its lead product candidate, MM120 ODT, aimed at treating generalized anxiety disorder and major depressive disorder. With over 25 years of experience in the life sciences sector, Roberts is expected to strengthen MindMed's financial structure and support the company's goals. Her previous accomplishments include pivotal roles during initial public offerings and significant acquisitions.
Read more →DFTXMindMed Reports First Quarter 2025 Financial Results and Recent Business Updates --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12
MindMed announced its first quarter financial results for 2025, highlighting significant business updates. The company has commenced dosing in the Phase 3 Emerge study for MM120 Orally Disintegrating Tablet (ODT) targeting Major Depressive Disorder (MDD), with topline data expected by 2026. Additionally, enrollment is proceeding well for the Voyage and Panorama studies for Generalized Anxiety Disorder (GAD). MindMed's current financial stability, supported by recent amendments to its loan agreement, positions it well for ongoing operational activities and prospective product launches.
Read more →DFTXMindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - Emerge is the first Phase 3 study of lysergide D-tartrate (LSD) in MDD; primary endpoint will measure change fro
MindMed has initiated the Phase 3 Emerge study for MM120 ODT, a novel treatment for Major Depressive Disorder (MDD), marking a significant step in the development of antidepressant therapies. The study will assess the drug's efficacy compared to a placebo, building on encouraging results from earlier phases. Approximately 140 participants are expected to enroll, with topline data anticipated in late 2026. The study aims to address the substantial unmet medical need among MDD patients who often do not respond adequately to existing treatments.
Read more →DFTXMindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anx
MindMed has reported its fourth quarter and full-year financial results for 2024, highlighting significant progress in its clinical development program. The company has dosed the first patients in Phase 3 studies for its MM120 Orally Disintegrating Tablet (ODT) targeting Generalized Anxiety Disorder and plans to initiate a similar study for Major Depressive Disorder in 2025. Financially, MindMed raised approximately $250 million in equity financing, which should sustain operations into 2027. The company also received breakthrough therapy designation from the FDA for MM120, indicating a positive outlook for future trials.
Read more →DFTXMindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder - Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint
MindMed has initiated its second Phase 3 trial, Panorama, for MM120 ODT, aimed at treating generalized anxiety disorder (GAD). This study will involve around 250 participants across the US and Europe, with a primary focus on measuring changes in anxiety levels via the Hamilton Anxiety Rating Scale over 12 weeks. The Panorama trial is built upon promising results from a previous Phase 2b study, which indicated a rapid and sustained response to MM120. Topline results from this new trial are expected in the latter half of 2026.
Read more →DFTXCorporate Presentation January 2025 Corporate Presentation | January 2025 This presentation (the "Presentation") has been prepared by Mind Medicine ( MindMed ) Inc. (" MindMed ", the "Company", "we", "our" or "us) solely
Mind Medicine (MindMed) released a corporate presentation detailing the progress and upcoming milestones for its investigational drug candidates, MM120 and MM402. The company anticipates significant clinical trial activities, including Phase 3 readouts for MM120, a treatment for major depressive disorder and generalized anxiety disorder. MindMed projects its cash runway will extend into 2027, providing funding for its ongoing development initiatives. However, the presentation highlights the inherent risks and uncertainties in the drug development process.
Read more →DFTXMindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the
MindMed has announced the first patient has been dosed in its Phase 3 Voyage study of MM120, a treatment for generalized anxiety disorder (GAD) using lysergide D-tartrate (LSD). This study follows encouraging Phase 2b results and aims to evaluate the efficacy and safety of MM120 through a randomized, double-blind approach. Approximately 200 participants will be enrolled in the U.S., with data expected by early 2026. The FDA has also granted Breakthrough Therapy Designation for MM120, highlighting its potential in addressing GAD, a condition affecting around 20 million people in the U.S.
Read more →DFTXMindMed Reports Third Quarter 2024 Financial Results and Business Updates --On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth qu
MindMed has announced its third quarter 2024 financial results, highlighting plans to initiate the Phase 3 Voyage study of MM120 ODT for Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024. The company is also set to launch two additional Phase 3 studies for MM120 ODT targeting GAD and Major Depressive Disorder (MDD) in the upcoming years. Despite facing operational costs, MindMed reported a significant cash reserve which is expected to fund operations into 2027. The topline data for the Voyage study is anticipated in the first half of 2026.
Read more →DFTXMindMed Reports Second Quarter 2024 Financial Results and Business Updates --Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM1
MindMed has reported its financial results for Q2 2024, highlighting progress in its clinical development programs. The company completed its End-of-Phase 2 meeting with the FDA and is on track to initiate a Phase 3 trial for MM120 ODT in Generalized Anxiety Disorder later this year. MindMed is also expanding its clinical pipeline with plans for a study in Major Depressive Disorder expected in the first half of 2025. Additionally, a new patent from the USPTO extends intellectual property protection for MM120 ODT until 2041.
Read more →DFTXMindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) -Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation
MindMed has reported a constructive End-of-Phase 2 meeting with the U.S. FDA regarding its clinical development of MM120 for Generalized Anxiety Disorder (GAD). The company has aligned with the FDA on the Phase 3 development strategy and plans to initiate clinical trials in the second half of 2024. Positive data from the completed Phase 2b clinical trial showed significant improvements in anxiety symptoms, offering hope for future treatment options for GAD. MindMed emphasizes the urgent need for innovation in GAD treatment, highlighting the challenges faced by millions living with this condition.
Read more →DFTXMindMed Reports First Quarter 2024 Financial Results and Business Updates --Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically s
MindMed reported its first quarter financial results for 2024, highlighting positive outcomes from its Phase 2b clinical trial of MM120 in Generalized Anxiety Disorder (GAD). The trial demonstrated statistically significant activity over 12 weeks, and the FDA granted Breakthrough Therapy Designation for MM120. The company's cash reserves stood at $252.3 million, expected to fund operations through 2026. Despite these positives, MindMed reported a significant net loss and increased general and administrative expenses compared to previous quarters.
Read more →DFTXMindMed Announces Voluntary Delisting from Cboe Canada All Common shares will remain listed on Nasdaq
MindMed Inc. has announced the voluntary delisting of its common shares from Cboe Canada, effective April 10, 2024, while maintaining its listing on Nasdaq. The decision was driven by the low trading volume on Cboe Canada, which no longer justified the associated costs. The company's board believes that consolidating its listing will enhance operational efficiency and redirect resources towards initiatives that increase shareholder value. Shareholders can still trade their shares on Nasdaq through their brokers, as the majority of Canadian brokers support this exchange.
Read more →DFTXMind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
Mind Medicine (MindMed) Inc. has announced the pricing of an underwritten offering of 16,666,667 common shares at $6.00 each, alongside a concurrent private placement of 12,500,000 shares at the same price. The total gross proceeds anticipated from these offerings is approximately $175 million. The transactions are set to close around March 11, 2024, pending normal closing conditions. Notably, these offerings involve several new investors and reflect an overall confidence in MindMed's future prospects in treating brain health disorders.
Read more →DFTXMM120 for Generalized Anxiety Disorder (GAD) Phase 2b Full Topline Data ODT PK Bridging Study Breakthrough Therapy Designation March 2024 Disclaimer This presentation (the "Presentation") has been prepared by Mind Medici
Mind Medicine (MindMed) Inc. has announced the topline results of its Phase 2b trial for MM120, a treatment for Generalized Anxiety Disorder (GAD), which has received Breakthrough Therapy Designation. This designation may expedite the development process due to the significant unmet need in this therapeutic area. The results suggest promising efficacy, marking a potential advancement in MindMed's pipeline focused on psychedelic and non-hallucinogenic treatments. However, the company faces challenges such as regulatory scrutiny and financial obligations as they move forward with their studies.
Read more →DFTXTHURSDAY MARCH 7, 2023, 6:00 AM EST MINDMED RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION AND ANNOUNCES POSITIVE 12-WEEK DURABILITY DATA FROM PHASE 2B STUDY OF MM120 FOR GENERALIZED ANXIETY DISORDER -A single oral admini
MindMed announced that the FDA has granted breakthrough therapy designation to its drug MM120 for generalized anxiety disorder (GAD). Positive results from a Phase 2b study demonstrated a 65% clinical response rate and significant improvements in anxiety symptoms sustained over 12 weeks. The company plans to engage with the FDA for an End-of-Phase 2 meeting in the first half of 2024, with a Phase 3 trial anticipated to start later that year. The drug was well-tolerated, with adverse events consistent with expected effects.
Read more →DFTXMindMed Reports 2023 Financial Results and Business Updates --Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple pl
MindMed has reported positive financial results and business updates for 2023, highlighting statistically significant Phase 2b data for MM120 in Generalized Anxiety Disorder. Upcoming milestones include a virtual investor event on March 7, 2024, where the company will share further data and discuss potential commercialization strategies. Additionally, MindMed initiated a Phase 1 trial for MM402 targeting Autism Spectrum Disorder, demonstrating the company's focus on expanding its pipeline. However, financial reports reveal an increase in net losses and rising R&D expenses.
Read more →DFTXMindMed Announces Business Update and Anticipated Milestones for 2024 -- Recently announced statistically significant and clinically meaningful topline Phase 2b data for MM-120 in Generalized Anxiety Disorder (GAD) posit
MindMed has reported a significant advancement in its clinical programs, particularly with MM-120 for Generalized Anxiety Disorder (GAD), showcasing statistically significant Phase 2b results indicating potential for improved treatments. The company plans to advance to Phase 3 clinical trials in the latter half of 2024, alongside sharing further data milestones throughout the year. However, a separate study assessing the effects of lysergide on Attention-Deficit/Hyperactivity Disorder did not achieve its primary goals, halting development in that area.
Read more →DFTXMindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in
MindMed announced positive topline results from its Phase 2b trial of MM-120 for generalized anxiety disorder, achieving its primary endpoint with statistically significant improvements in Hamilton Anxiety rating scale scores. The trial showed a 7.6-point greater reduction in anxiety symptoms for those receiving MM-120 compared to placebo at Week 4, with a clinical response rate of 78% in the highest dose group. The company plans to request an End-of-Phase 2 meeting with the FDA and initiate Phase 3 trials in 2024. Safety results were favorable, although some participants experienced mild to moderate adverse events.
Read more →DFTXMindMed Reports Third Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of
MindMed reported its third-quarter 2023 financial results, highlighting the upcoming topline readout of MM-120 in a Phase 2b trial for generalized anxiety disorder (GAD) expected in Q4 2023. The company also plans to initiate a Phase 1 trial for MM-402 targeting autism spectrum disorder (ASD) within the same timeframe. Despite a cash reserve of $117.7 million, MindMed recorded a net loss of $17.9 million, reflecting financial pressures during increasing R&D activities. Management is set to provide further details in a conference call today.
Read more →DFTXCompany Logo MindMed Investor Presentation August 2023 Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed” or the “Company
Mind Medicine (MindMed) Inc. has released its August 2023 investor presentation, highlighting its position as a leader in brain health with a focus on psychedelic-inspired therapies. The presentation outlines a diversified pipeline of clinical programs, including MM-120 for Generalized Anxiety Disorder and MM-402 for Autism Spectrum Disorder, with pivotal results anticipated by Q4 2023. Despite emphasizing its strengths, the company has cautioned investors about inherent risks in forward-looking statements and the uncertainty surrounding clinical trial successes and regulatory approvals.
Read more →DFTXMindMed Reports Second Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline
MindMed reported its financial results for Q2 2023, highlighting several upcoming milestones, including a topline readout for MM-120 in generalized anxiety disorder (GAD) expected in Q4 2023. The company is concluding enrollment in its Phase 2b study and has entered an exclusive licensing agreement with Catalent for its innovative Zydis ODT formulation. The company’s cash reserves are projected to fund operations into the first half of 2025. However, it faces a significant increase in net loss and higher operational expenses compared to the previous year.
Read more →DFTXMindMed Investor Presentation Investor Day 2023: MM-120 for Generalized Anxiety Disorder Disclaimer This presentation (the “Presentation”) has been prepared by Mind Medicine (MindMed) Inc. (“MindMed&
MindMedicine (MindMed) Inc. held its Investor Day 2023 presentation focusing on its drug candidate MM-120 for Generalized Anxiety Disorder (GAD). The event included discussions on the unmet needs, patient journeys, and the potential benefits of monitored therapies. Experts shared insights about MindMed's prospects in clinical development and upcoming milestones, although the presentation cautioned against the reliance on forward-looking statements due to inherent risks in drug development. Additionally, MindMed emphasized its focus on regulatory compliance and research within approved frameworks.
Read more →DFTXMindMed Adjourns Annual General Meeting of Shareholders Meeting Will Resume on Wednesday
MindMed Inc. adjourned its Annual General Meeting of Shareholders due to insufficient quorum and will reconvene on June 21, 2023. The company believes that representatives of FCM MM Holdings intentionally disrupted quorum requirements to limit shareholder input. MindMed is urging shareholders to vote for its director nominees on the WHITE proxy card, emphasizing the importance of participation in the upcoming meeting. The new proxy voting deadline is set for June 19, 2023.
Read more →DFTXMindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting – Preclinical data in ASD model demonstrate prosocial effects of MM-4
MindMed is set to present preclinical data on MM-402, an R-enantiomer of MDMA, at the ASCP 2023 Annual Meeting from May 30 to June 2, 2023. The data indicate that MM-402 significantly increases social interaction in a model for autism spectrum disorder (ASD) without the hyperactivity seen with standard MDMA. The company plans to begin its first clinical trial of MM-402 later this year. This research represents a potential advancement in treating social functioning in individuals with ASD.
Read more →DFTXMindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD) – Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results
MindMed has announced that its Phase 2b clinical trial of MM-120 for Generalized Anxiety Disorder (GAD) has surpassed the enrollment milestone of 50% across 20 active sites. The trial aims to enroll up to 200 participants who will receive either MM-120 or a placebo. CEO Robert Barrow highlighted the efficient recruiting process, which included 25 patients enrolled in the last month alone. Results from the trial are anticipated to be released in late 2023.
Read more →DFTXMindMed Reports First Quarter 2023 Financial Results and Business Highlights – Key MM-120 readouts in GAD (Phase 2b) and ADHD (Phase 2a) expected by end of 2023 – – MM-402 pre-clinical data in ASD mo
MindMed reported its financial results for Q1 2023, indicating a strong cash position of $129.4 million that is expected to fund operations through the first half of 2025. Key milestones include expected readouts from Phase 2 studies of MM-120 for generalized anxiety disorder and ADHD by the end of the year, and the development of MM-402 for autism spectrum disorder. Despite a net loss of $24.8 million for the quarter, the company remains focused on advancing its research and development pipeline. Recent leadership changes aim to bolster corporate governance and operational efficiencies.
Read more →DFTXMindMed Files Preliminary Proxy Statement for 2023 Annual Meeting Presents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and Highly Qualified, New Independent Candidate David W. Grys
MindMed has filed its preliminary proxy statement for the upcoming 2023 Annual Meeting, presenting a slate of highly qualified director nominees, including five incumbents and new independent candidate David W. Gryska. The company highlights its positive R&D momentum, notably recent favorable trial results. However, FCM MM Holdings intends to contest the board's election by nominating their own candidates, which the existing board views as a potential threat to strategy and shareholder interests. The board is committed to engaging with shareholders and strengthening its leadership ahead of the meeting.
Read more →DFTXMindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD) – Primary endpoint achieved statistically significant improvement in MDD symptoms  
MindMed has announced positive topline data from a Phase 2 trial of lysergide in treating Major Depressive Disorder (MDD). The trial demonstrated significant improvements in MDD symptoms, with the high-dose group showing a notable reduction in scores compared to a lower-dose control group. These findings, presented in Basel on April 14, 2023, reinforce the potential of lysergide in treating brain health disorders, particularly in relation to MindMed's MM-120 program for Generalized Anxiety Disorder. The investigational drug was well-tolerated, which is crucial for its further development.
Read more →DFTXMindMed Reports Full Year 2022 Financial Results and Business Highlights – Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – – Company to
MindMed has reported its financial results for 2022, highlighting a strong cash position of $142.1 million and a commitment to research and development. The company is set to announce key data from its Phase 2b trial of MM-120 for generalized anxiety disorder and Phase 2a trial for ADHD later in 2023. Additionally, it plans to initiate its first clinical trial of MM-402, aimed at treating autism spectrum disorder, within the year. Overall, the company is focused on advancing its pipeline and improving outcomes for brain health disorders.
Read more →DFTXMindMed Provides Corporate Update and 2023 Outlook - Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 - Company to initiate first clinical trial of MM-402 in 2
MindMed Inc. has provided a corporate update focusing on its product candidates for brain health disorders. The company anticipates significant data readouts from its MM-120 product in late 2023, including studies for generalized anxiety disorder and ADHD. Additionally, MindMed plans to initiate its first clinical trial for MM-402 within the same timeframe. Despite a strong cash position expected to sustain operations until mid-2025, the company acknowledges the various risks associated with clinical trials and regulatory processes.
Read more →DFTXMindMed Reports Third Quarter 2022 Financial Results and Business Highlights – Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder with first patients dosed in Q3 2022 and expect key cli
MindMed Reports Third Quarter 2022 Financial Results and Business Highlights Phase 2b dose-optimization trial in patients with Generalized Anxiety Disorder with first patients dosed in Q3 2022 and expect key clinical readout in late 2023 Advanced IND-enabling studies for MM-402
Read more →DFTXMindMed Announces Proposed Public Offering of Common Shares New York
MindMed Announces Proposed Public Offering of Common Shares New York, September 27, 2022 (GLOBE NEWSWIRE) Mind Medicine (MindMed) Inc. ( MindMed ) (Nasdaq: MNMD) (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, t
Read more →DFTXMindMed Announces Compliance with Nasdaq Listing Requirements
MindMed Announces Compliance with Nasdaq Listing Requirements NEW YORK, Sept. 14, 2022 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the Company or MindMed ), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, toda
Read more →DFTXMindMed Completes 1-for-15 Reverse Share Split - Common shares will begin trading on a split-adjusted basis at market open on
1-for-15 Reverse Share Split - Common shares will begin trading on a split-adjusted basis at market open on August 29, 2022 - NEW YORK, August 26, 2022 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the Company or MindMed ), a clinical stage biopharmaceutical comp
Read more →DFTXMindMed Reports Second Quarter 2022 Financial Results and Business Highlights – Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 &#x
MindMed Reports Second Quarter 2022 Financial Results and Business Highlights Phase 2b dose-optimization trial in patients with General Anxiety Disorder underway with first patient dosing expected in Q3 2022 Advanced IND-enabling studies for MM-402 with the Phase 1 investigator
Read more →DFTXCorporate Overview | July 2022 3 Corporate Overview | July 2022 4
Corporate Overview | July 2022 3 Corporate Overview | July 2022 4
Read more →DFTXMindMed Reports First Quarter 2022 Financial Results and Business Highlights - Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal, MD as
MindMed Reports First Quarter 2022 Financial Results and Business Highlights - Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal, MD as Chief Commercial Officer - - Cash runway through key cli
Read more →DFTXMindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders - Results from the placebo-controlled investigator-initiated trial, conducted at the
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders - Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB), demonstrate the signifi
Read more →DFTXMindMed Corporate Over April 2022 Disclaimer This presentation (the Presentation ) has been prepared by Mind Medicine (MindMed) Inc. ( MindMed or the Company ) solely for informational purposes. None of MindMed, its affi
MindMed Corporate Over April 2022 Disclaimer This presentation (the Presentation ) has been prepared by Mind Medicine (MindMed) Inc. ( MindMed or the Company ) solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, of
Read more →DFTXMindMed Reports Full Year 2021 Financial Results and Business Highlights - FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 - - Progressed development progra
MindMed Reports Full Year 2021 Financial Results and Business Highlights - FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 - - Progressed development programs for all three lead product candidates - - Cash balance
Read more →DFTXMindMed Announces Transition of
MindMed Announces Transition of CFO NEW YORK, March 25, 2022 Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the Company or MindMed ), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief
Read more →DFTXFDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder - FDA clearance leads to first commercial IND for LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder - FDA clearance leads to first commercial IND for LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022 - NEW YORK, January 25, 2021 -- Mind Medicine (MindMed) Inc.
Read more →DFTXStephen Hurst Resigns from MindMed Board of Directors
Stephen Hurst Resigns from MindMed Board of NEW YORK, January 7, 2022 -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Steve Hurst from his r
Read more →DFTXMindMed Announces Transitions to Management Team -Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor
MindMed Announces Transitions to Management -Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor- NEW YORK, December 29, 2021-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),
Read more →DFTXMindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder - FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder - FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder- NEW YORK,
Read more →DFTXMindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD - Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD - Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands - -Trial led by Dr. Matthi
Read more →DFTXMindMed Appoints Robert Barrow as Chief Executive Officer and Director -Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed- -Carol Vallone appointed as Chair of the B
MindMed Appoints Robert Barrow as Chief Executive Officer and Director -Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed- -Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Chai
Read more →DFTXForm 51-102F3 Material Change Report Item 1 Name and Address of Company Mind Medicine (MindMed) Inc. (the " Company ") 1055 West Hastings Street, Suite 1700 Vancouver, British Columbia V6E 2E9 Item 2 Date of Material Cha
Material Change Report Mind Medicine (MindMed) Inc. (the "Company") 1055 West Hastings Street, Suite 1700 Vancouver, British Columbia On December 14, 2021, a news release was disseminated through the newswire services of GlobalNewswire and subsequently filed on SEDAR at www.
Read more →DFTXMindMed Engages in Productive Pre-Submission
RELEASE: December 9, 2021 MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedel
Read more →DFTXMindMed to Participate at the Benzinga Global Small Cap Conference
MindMed to Participate at the Benzinga Global Small Cap Conference NEW YORK, December 2, 2021-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindM
Read more →DFTXNOTICE OF CHANGE OF AUDITOR PURSUANT TO NATIONAL INSTRUMENT 51-102 OF THE CANADIAN SECURITIES ADMINISTRATORS TO: ONTARIO SECURITIES COMMISSION BRITISH COLUMBIA SECURITIES COMMISSION ALBERTA SECURITIES COMMISSION THE MANI
NOTICE OF CHANGE OF AUDITOR PURSUANT TO NATIONAL OF THE CANADIAN SECURITIES ADMINISTRATORS TO: ONTARIO SECURITIES COMMISSION BRITISH COLUMBIA SECURITIES COMMISSION ALBERTA SECURITIES COMMISSION THE MANITOBA SECURITIES COMMISSION FINANCIAL AND CONSUMER SERVICES COMMISSION (N
Read more →DFTXto Present at H.C.
FOR IMMEDIATE RELEASE: December CONTACT: mindmed@150bond.com to Present at H.C. Wainwright 2nd Annual Psychedelics Conference Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, t
Read more →DFTXEhhibit 99.1 FOR IMMEDIATE RELEASE
IMMEDIATE RELEASE: November 16, 2021 MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announc
Read more →DFTXMindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline New York, NY
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline New York, NY - November 15, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company deve
Read more →DFTXMind Medicine (MindMed) Inc. Condensed Consolidated Interim Financial Statements (Expressed in Thousands of United States Dollars) For The Three and Nine Months Ended
Mind Medicine (MindMed) Inc. Condensed Consolidated Interim Financial Statements (Expressed in Thousands of United States Dollars) For The Three and Nine Months Ended September 30, 2021 and September 30, 2020 Mind Medicine (MindMed) Inc. Condensed Consolidated Interim State
Read more →DFTXat the Jefferies London Healthcare Conference
FOR IMMEDIATE RELEASE: November 12, 2021 CONTACT: mindmed@150bond.com at the Jefferies London Healthcare Conference Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pl
Read more →DFTXMindMed Appoints Dr.
FOR IMMEDIATE RELEASE: November 5, 2021 CONTACT: mindmed@150bond.com MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired
Read more →DFTXMindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA
FOR IMMEDIATE RELEASE: October 26, 2021 CONTACT: mindmed@150bond.com MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Mind Medicine (MindMed) Inc. (NASDAQ: MNMD, NEO: MMED, DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspire
Read more →DFTXMindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton NEW YORK - September 30, 2021 - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; "MindMed" or the "Company"), a leading biotech company developing psych
Read more →DFTXForm 51-102F3 Material Change Report Item 1 Name and Address of Company Mind Medicine (MindMed) Inc. (the " Company ") 1166 Alberni Street, Suite 1604, Vancouver, British Columbia V6E 3Z Item 2 Date of Material Change
Material Change Report Mind Medicine (MindMed) Inc. (the "Company") 1166 Alberni Street, Suite 1604, Vancouver, British Columbia On September 30, 2021, a news release was disseminated through the newswire services of GlobalNewswire and subsequently filed on SEDAR at www.seda
Read more →DFTXMindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes NEW YORK, September 2, 2021 -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-ins
Read more →DFTXMINDMED ANNOUNCES COLLABORATION WITH FORIAN
FOR IMMEDIATE RELEASE: August 24, 2021 CONTACT: mindmed@150bond.com MINDMED ANNOUNCES COLLABORATION WITH FORIAN TO ADVANCE DEVELOPMENT OF PERSONALIZED PSYCHIATRY FOR ANXIETY DISORDERS New York, New York - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (t
Read more →DFTXMindMed Joins Critical Path Institute's Patient-Reported Outcome
FOR IMMEDIATE RELEASE: August 17, 2021 CONTACT: mindmed@150bond.com MindMed Joins Critical Path Institute's Patient-Reported Outcome Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired
Read more →DFTXMindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline New York, NY
2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline New York, NY - August 13, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announc
Read more →DFTXMindMed Discover. Develop. Deploy. www.mindmed.co Psychedelic Inspired Medicines August 2021 MMED MNMD MMQ NASDAQ NEO DE MindMed Disclaimer Corporate Presentation | August 2021 MindMed 1 This presentation (the "Presentat
MindMed Discover. Develop. Deploy. www.mindmed.co Psychedelic Inspired Medicines August 2021 MMED MNMD MMQ NASDAQ NEO DE MindMed Disclaimer Corporate Presentation | August 2021 MindMed 1 This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("M
Read more →DFTXMind Medicine (MindMed) Inc. Condensed Consolidated Interim Financial Statements (Expressed in Thousands of United States Dollars) For The Three and Six Months Ended
Mind Medicine (MindMed) Condensed Consolidated Interim Financial Statements (Expressed in Thousands of United States Dollars) For The Three and Six Months Ended June 30, 2021 and Mind Medicine (MindMed) Inc. Condensed Consolidated Interim Statements of Financial Position (E
Read more →DFTXMindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board New York, NY
Dr. Robert Dworkin to Scientific Advisory Board New York, NY - August 10, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board
Read more →DFTXMindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology New York, NY
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology New York, NY - August 3, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participa
Read more →DFTXMindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT New York, NY
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT New York, NY - July 28, 2021 - MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical tri
Read more →DFTXMindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit New York, NY
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit New York, NY - July 12, 2021 - MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce tha
Read more →DFTXMindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company New York, NY
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company New York, NY - July 8, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in
Read more →DFTXMindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board New York, NY
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board New York, NY - June 23, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition
Read more →DFTXMindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board New York, NY
Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board 17, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leadi
Read more →DFTXMindMed Announces Chief Executive Officer Transition New York, NY
Chief Executive Officer Transition June 9, 2021 - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD, NEO: MMED, DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's
Read more →DFTXMIND MEDICINE (MINDMED) INC. (the "Corporation") ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS REPORT OF VOTING RESULTS Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations The followin
MIND MEDICINE (MINDMED) INC. ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS REPORT OF VOTING RESULTS Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations The following briefly describes the matters voted upon and the outcome of votes at the
Read more →DFTXMindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing New York, NY
MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing New York, NY - May 26, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of
Read more →DFTXMindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System New York, NY
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System New York, NY - May 24, 2021 - MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israe
Read more →DFTXMindMed Announces the Approval of Mescaline Study BASEL, SWITZERLAND
MindMed Announces the Approval of Mescaline BASEL, SWITZERLAND - May 20, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evalu
Read more →DFTXThe Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing New York, NY
The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing York, NY - May 18, 2021 - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD, NEO: MMED, DE: MMQ) ("MindMed" or the "Company"), a leading clinical stage p
Read more →DFTXMindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication New York, NY
FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication New York, NY - May 17, 2021 - MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedeli
Read more →DFTXMindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development New York, NY
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development New York, NY - May 13, 2021 - MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of
Read more →DFTXMindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics New York, NY
Project Angie, Targeting the Treatment of Pain with Psychedelics New York, NY - May 5, 2021 - Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic-inspired medicine company announces the launch of its Project Angie
Read more →DFTXNOTICE OF ANNUAL AND SPECIAL MEETING AND MANAGEMENT INFORMATION CIRCULAR WITH RESPECT TO THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF MIND MEDICINE (MINDMED) INC. TO BE HELD ON MAY 27, 2021 These materials are impor
NOTICE OF ANNUAL AND SPECIAL MEETING AND MANAGEMENT INFORMATION CIRCULAR WITH RESPECT TO THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF MIND MEDICINE (MINDMED) INC. TO BE HELD ON MAY 27, 2021 These materials are important and require your immediate attention. If you have
Read more →DFTXMindMed Begins Trading on Nasdaq New York, NY
April 27, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech company, is pleased to announce the start of trading on The Nasdaq Capital Market ("Nasdaq"). Trading will begin on Tuesday, April 27, 2021, under the symbol "MNMD" on the Nasdaq
Read more →DFTXMindMed To Commence Trading on Nasdaq New York, NY
MindMed To Commence Trading New York, NY - April 23, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech company, announced today that the Company's subordinate voting shares have been approved for listing on The Nasdaq Capital Market ("Na
Read more →Competitive Position
How DFTX ranks across every disease it competes inCompetitive Position is a premium feature
See how DFTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial